Metabolic Complete Response of Metastatic Oncogene-Negative, PDL1-Negative Non-Small Cell Lung Cancer After Chemo-Immunotherapy and Radiotherapy: A Case Report

A 71-year-old male ex-smoker presented in October 2021 to our department with a brain and bone metastatic adenocarcinoma NSCLC. PDL1, ROS, EGFR, and ALK were negative. He underwent stereotactic radiotherapy for brain metastases. In November 2021, he started a chemotherapy (CHT) regimen with cisplati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current oncology (Toronto) 2024-12, Vol.31 (12), p.8118-8126
Hauptverfasser: Surgo, Alessia, Davì, Valerio, Ciliberti, Maria Paola, Carbonara, Roberta, Caliandro, Morena, Di Guglielmo, Fiorella Cristina, Sasso, Nicola, Calbi, Roberto, Gentile, Maria Annunziata, Talienti, Tiziana, Bruno, Isabella, Troia, Michele, Bonaparte, Ilaria, Ludovico, Giuseppe Mario, Surico, Giammarco, Fiorentino, Alba
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A 71-year-old male ex-smoker presented in October 2021 to our department with a brain and bone metastatic adenocarcinoma NSCLC. PDL1, ROS, EGFR, and ALK were negative. He underwent stereotactic radiotherapy for brain metastases. In November 2021, he started a chemotherapy (CHT) regimen with cisplatin (75 mg/m every 21 days) and pemetrexed (500 mg/m every 21 days), and ICI with Atezolizumab (1200 mg every 21 days). In July 2022, RT to the lung tumor and mediastinal nodal was performed with a total dose of 45 Gy in 15 fractions. He continued with immunotherapy until December 2022, when a grade 3-4 toxicity from immunotherapy was observed (hypothyroidism, psoriasis, and cystitis). He achieved a complete clinical response to the therapy. To date, the patient is alive, with a complete metabolic response, without treatment at 37 months from diagnosis.
ISSN:1718-7729
1198-0052
1718-7729
DOI:10.3390/curroncol31120598